Albiglutide
Also known as: Tanzeum, Eperzan
Once-weekly GLP-1 receptor agonist fused to albumin, FDA-approved in 2014 as Tanzeum for type 2 diabetes. Discontinued commercially in 2018.
Last updated
Mechanism of Action
Albiglutide is two tandem copies of a DPP-4-resistant GLP-1 analog genetically fused to human albumin. The albumin fusion slows clearance and gives a multi-day half-life. It activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, suppressing glucagon and slowing gastric emptying.
- Half-life
- ~5 days
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Improved glycemic control in type 2 diabetes (HARMONY program)
- Reduced major adverse cardiovascular events in Harmony Outcomes
- Low rates of nausea compared with some GLP-1 agonists
Potential Side Effects
- Diarrhea and nausea
- Injection-site reactions
- Boxed warning: thyroid C-cell tumors in rodents
- Pancreatitis (warning)
- Hypoglycemia with insulin or sulfonylureas
Common Dosing
When marketed, labeled dosing was 30 mg subcutaneously once weekly, which could be increased to 50 mg once weekly. The product is no longer sold; dosing of any GLP-1 therapy is set and supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Serious hypersensitivity to albiglutide
No documented stacking partners for Albiglutide yet.
- View
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
2018
- View
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin
2014